Bioness Medical Inc.

Bioness operates at the intersection of medical devices, rehabilitation robotics, functional electrical stimulation, and clinical software. Its portfolio spans lower-limb systems such as L300 Go and L360 Thigh, upper-limb stimulation through H200 Wireless, and body-weight-supported gait training through Vector and HaloPlex. That breadth gives the company exposure across home-use mobility support and institutional rehabilitation workflows rather than a single-device niche. Bioness also differentiates through the Bioness Integrated Therapy System, which combines visual, auditory, cognitive, motor, and balance assessment with therapy activities, and through its patient and clinician app ecosystem. Its 2026 PoNS clearance and OneStep collaboration strengthen its relevance in stroke recovery and data-driven mobility care, while the 2024 acquisition by Accelmed provides a new ownership context.

Bioness shows a trajectory centered on portfolio expansion and commercialization rather than rapid disclosed headcount growth. Founded in 2004, the company re-established itself as an independent neurorehabilitation-focused organization on Jan 8, 2025. It acquired Harmonic Bionics on Jun 18, 2025 and the Portable Neuromodulation Stimulator System on Apr 9, 2026, broadening its capabilities in robotics and neuromodulation. Regulatory progress became a major 2026 inflection point: PoNS received FDA 510(k) clearance on Jun 29, 2026 for chronic-stroke-related gait deficits. Bioness then added clinical leadership with Antonella Favit-Van Pelt as Chief Medical Officer on Jun 25, 2026, launched a OneStep collaboration on Sep 9, 2026, and commercially launched HaloPlex on Sep 21, 2026. Financially, the company raised $10 million in debt financing from Horizon Technology Finance on Sep 2, 2026, although contemporaneous public announcements referenced a larger $15 million credit facility, creating a funding disclosure discrepancy. Accelmed announced a $45 million cash acquisition of Bioness on Oct 1, 2024.